Treatment With PARP Inhibitors for Patients With Ovarian Cancer

PAOLA-1 Shows Benefit from Olaparib After Bevacizumab in Ovarian Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.

Niraparib Maintenance Shows Continued PFS Improvement in Ovarian Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul DiSilvestro, MD, discussed the results of the PRIMA trial of niraparib maintenance therapy for patients with advanced ovarian cancer. This is the second of 3 articles based on this event.

Long-Term Follow-Up Shows Olaparib’s Efficacy in Ovarian Cancer

During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.

Part 2: Using PARP Inhibitors Beyond Recommended Duration in Ovarian Cancer

During a live virtual event, Adam C. ElNaggar discussed with participants whether patients who respond to PARP inhibitors for advanced ovarian cancer should continue to receive them indefinitely.

Part 1: Addressing Toxicities of PARP Inhibitors for Ovarian Cancer

During a live virtual event, Adam C. ElNaggar, MD, discussed with participants their experiences with PARP inhibitors in patients with ovarian cancer.

Part 2: Anderson Reviews Niraparib’s Efficacy in High-Risk Ovarian Cancer

During a live virtual event, Matthew L. Anderson, MD, PhD, discussed the results of the PRIMA study of niraparib in patients with wild-type and BRCA-mutated ovarian cancer.

Part 1: PARP Inhibition Recommendations in Advanced Ovarian Cancer

During a live virtual event, Matthew L. Anderson, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for treating patients with advanced ovarian cancer using PARP inhibitors based on BRCA mutation status and other factors.